SCHEMBL8515666

SCHEMBL8515666

CC12CCOC1C(=O)c1cc(Br)ccc1O2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.40
CYP19A1 P11511 1/20 0.40
MALT1 Q9UDY8 1/20 0.39
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 2/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HIF1A Q16665 1/20 0.34
HSD11B1 P28845 1/20 0.33
BCHE P06276 1/20 0.32
APP P05067 2/20 0.32
AR P10275 1/20 0.32
S100A4 P26447 1/20 0.32
CTSD P07339 1/20 0.32
BACE1 P56817 1/20 0.32
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9882483 1.00 PBRM1 (0.40) PBRM1CYP19A1MALT1MEN1KMT2A
SCHEMBL12489864 0.93 PBRM1 (0.38) PBRM1CYP19A1MALT1MEN1KMT2A
SCHEMBL12489867 0.93 PBRM1 (0.38) PBRM1CYP19A1MALT1MEN1KMT2A
SCHEMBL9882489 0.85 PBRM1 (0.34) PBRM1MALT1MAPTLMNAHTT
SCHEMBL8515927 0.85 PBRM1 (0.34) PBRM1MALT1MAPTLMNAHTT
SCHEMBL8532115 0.80 CYP19A1 (0.40) PBRM1CYP19A1MALT1MEN1KMT2A
SCHEMBL9882535 0.80 CYP19A1 (0.40) PBRM1CYP19A1MALT1MEN1KMT2A
SCHEMBL8532112 0.80 CYP19A1 (0.40) PBRM1CYP19A1MALT1MEN1KMT2A
SCHEMBL12490443 0.76 PPIB (0.43) CYP19A1MALT1MEN1KMT2AMAPT
SCHEMBL8515320 0.76 PPIB (0.43) CYP19A1MALT1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157448-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES GENENTECH, INC. 2012-06-21 US disclosed
WO-2012071458-A1 HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157448-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES BACE1, PSEN1, PSEN2 PBRM1 3853/4885CYP19A1 2497/4885MALT1 4452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.